Lung Neoplasms clinical trials

The registry lists 5,422 studies for Lung Neoplasms across more than 10 countries. 1,346 are recruiting or about to start. 2,751 of them are mainly about Lung Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 8 narrower conditions too, such as Carcinoma, Non-Small-Cell Lung: 12,578 studies, 3,222 open.

ClinicalTrials.gov finds 14,711 studies for Lung Neoplasms. How that becomes 5,420 here

This page counts the studies the registry files under Lung Neoplasms, and those it files under no condition that list Lung Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

14,711Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−7,135Filed under a narrower condition, counted on its own pageCarcinoma, Non-Small-Cell Lung 5,314 · Small Cell Lung Carcinoma 730 · Mesothelioma, Malignant 254 · Adenocarcinoma of Lung 132 · Multiple Pulmonary Nodules 57 · Carcinoma, Bronchogenic 17 · 2 more
−174List Lung Neoplasms as a condition, but the registry did not file them under itMost often written as “Lung Cancer Screening” (11), “Squamous Cell Lung Cancer” (9), and “Non-small Cell Lung Cancer Metastatic” (7). The registry filed them under other conditions only, most often Neoplasms (22) and Neoplasm Metastasis (21).
−1,982Match it another way662 name it in the title, 34 in a keyword, and 1,286 by a synonym or other text the search reads.
5,420The count on this page147 of them list Lung Neoplasms in their own words; the registry filed them under no condition.

Get an email when these change. Save the Lung Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 2,374
Recruiting: 996
Status unknown: 629
Terminated: 506
Active, not recruiting: 356
Not yet recruiting: 313

Phase

Phase 2: 1,457
Phase 1: 894
Phase 3: 366
Phase 4: 73
Early Phase 1: 65

Where

United States: 2,459
China: 842
France: 399
Canada: 382
Italy: 298
United Kingdom: 275

Who runs them

M.D. Anderson Cancer Center (162) · National Cancer Institute (NCI) (133) · Memorial Sloan Kettering Cancer Center (108) · Alliance for Clinical Trials in Oncology (84) · AstraZeneca (61) · Massachusetts General Hospital (49) · Mayo Clinic (47) · National Taiwan University Hospital (46)

What is being tested here

Drugs under test in Lung Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Durvalumab	10	5	44
Osimertinib	10	4	30
Carboplatin	9	27	156
Pembrolizumab	9	8	38
Pemetrexed	6	11	70
Bevacizumab	6	7	62
Andamertinib	6	2	8
Paclitaxel	5	20	118
Cisplatin	5	24	113
Atezolizumab	5	2	20

Drug classes tested here Immune checkpoint inhibitors 61 open · Tyrosine kinase inhibitors (TKIs) 52 open · Antibody-drug conjugates (ADCs) 12 open · Antimetabolites 11 open · Angiogenesis inhibitors 9 open

Coming up

86phase 3 studies under way

537studies finish main data collection within a year18 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung · Phase 3 · Vergent Bioscience, Inc.
Dec 2026Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy · Phase 3 · Zhou Chengzhi
Dec 2026Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment · Phase 3 · Boehringer Ingelheim
Dec 2026Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) · Phase 3 · Qilu Pharmaceutical Co., Ltd.
Dec 2026Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer · Phase 3 · M.D. Anderson Cancer Center
Dec 2026Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer · Phase 3 · Canadian Cancer Trials Group
Dec 2026MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) · Phase 3 · Guangdong Association of Clinical Trials
Jan 2027Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study · Phase 3 · Yang Hong
Mar 2027Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer · Phase 3 · M.D. Anderson Cancer Center
Mar 2027Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer · Phase 3 · City of Hope Medical Center

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 683 (69%) set no upper age limit and 142 (14%) stop at 75 or younger. 45 (5%) take children under 18. 6 (1%) are for women only and 2 (<1%) for men only; 142 (14%) take healthy volunteers.

Recruiting studies that take each age, of 996
Age	Women	Men
10	37 (4%)	37 (4%)
18	838 (84%)	834 (84%)
30	894 (90%)	890 (89%)
40	914 (92%)	910 (91%)
50	971 (97%)	967 (97%)
65	987 (99%)	983 (99%)
75	946 (95%)	943 (95%)
85	756 (76%)	753 (76%)

Across all 5,422 studies, recruiting or not: 12% stop at 75 or younger and 2% at 65; 6% take children; 1% are for women only and <1% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lung Neoplasms studies take

Of 364 phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 65 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	52 mo28–74 · 290 studies	41 mo25–57 · 127 studies	60 mo35–90 · 163 studies
Phase 1/2	54 mo40–93 · 157 studies	48 mo37–82 · 79 studies	60 mo44–159 · 78 studies
Phase 2	65 mo34–105 · 364 studies	37 mo23–61 · 77 studies	72 mo43–113 · 287 studies
Phase 3	43 mo30–80 · 128 studies	36 mo23–44 · 62 studies	66 mo42–99 · 66 studies
Phase 4	35 mo24–67 · 28 studies	—	—
Interventional, no phase	34 mo15–67 · 915 studies	17 mo8–34 · 51 studies	35 mo16–68 · 864 studies
Observational	57 mo25–135 · 681 studies	48 mo24–58 · 90 studies	65 mo25–162 · 591 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting23

PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging TechniqueNov 10, 2026NCT06914427
Development of Clinical and Biological Database on Bronchial CancerNov 6, 2026NCT07085429
SI-B036-ST-101 in Advanced/Metastatic Solid TumorsNov 4, 2026NCT07857616
ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung CancerNov 3, 2026NCT07786909
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in RadiotherapyOct 29, 2026NCT07185958

Show 18 more

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung CarcinomaOct 28, 2026NCT06014827
Feasibility and Uptake of Low-Dose CT Lung Cancer Screening in KuwaitOct 28, 2026NCT07766538
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving LorlatinibOct 27, 2026NCT07782359
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in CanadaOct 26, 2026NCT07536178
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung CancerOct 23, 2026NCT07432802
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)Oct 23, 2026NCT07472478
BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor MalignanciesOct 23, 2026NCT07789912
Short-term Effects of Osteopathic Manipulations on Heart Rate Variability in Lung Cancer Patients - A Randomized Pilot StudyOct 21, 2026NCT06822348
Telerehabilitation Exercise Program for Postoperative Recovery in Lung Cancer.Oct 21, 2026NCT07861282
Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung CancerOct 20, 2026NCT07436858
Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung CancerOct 19, 2026NCT06791057
An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS TrialOct 16, 2026NCT07615764
OPTIMISE Lung SABROct 16, 2026NCT07777614
Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body RadiotherapyOct 15, 2026NCT07289646
Primary Radiotherapy In MEtastatic Lung CancerOct 14, 2026NCT07135882
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionOct 13, 2026NCT07128199
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)Oct 13, 2026NCT07393555
CAIX-targeted PET/CT in Solid TumorsOct 13, 2026NCT07833085

Show 22 more

The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung CancerNov 3, 2026NCT07913256
Patient Needs and Preferences for NSCL Cancer Treatment MonitoringNov 2, 2026NCT07909343
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung CancerNov 2, 2026NCT07910942
Development and Utilization of an Integrated Clinical Genomic DatabaseNov 2, 2026NCT07911267
Snakehead Fish Extract and Curcumin Co-Supplementation in Advanced Lung Cancer on Inflammation, Nutritional Status, and Quality of LifeOct 30, 2026NCT07906626
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic CarcinomaOct 29, 2026NCT07902921
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.Oct 29, 2026NCT07903415
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC PatientsOct 27, 2026NCT07897734
Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung TumorsOct 27, 2026NCT07898241
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung CancerOct 26, 2026NCT07894458
Clinical Application of Artificial Intelligence Methods in Diagnostic Imaging of Pulmonary NodulesOct 26, 2026NCT07895147
Longitudinal AI-Assisted Management of Indeterminate Pulmonary NodulesOct 26, 2026NCT07895277
Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerOct 23, 2026NCT07892300
Pulsed Field Ablation for the Treatment of Malignant Lung TumorsOct 22, 2026NCT07889297
The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant TumorsOct 22, 2026NCT07890038
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLCOct 22, 2026NCT07890636
Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung CancerOct 20, 2026NCT07882628
Union-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung CanceOct 20, 2026NCT07882758
Surgical Margin Assessment Using Intra-operative High-resolution PET/CT in Patients With Cancers Referred to Surgical Resection, an Exploratory Pilot StudyOct 20, 2026NCT07884487
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II StudyOct 16, 2026NCT07878871
Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLCOct 14, 2026NCT07874464
Lung Cancer Detection in Never Smokers Using Urine Volatile Organic Compound (VOCs)Oct 13, 2026NCT07871656

Studies

Recruiting first, then most recently updated. Showing 50 of 5,422. Browse all 5,422 → or search them.